InflaRx
Jena
About InflaRx
InflaRx develops new therapeutics in the field of acute and chronic inflammation and consists of a team of internationally recognized researchers and clinicians who have dedicated their careers to translate discoveries and expertise into new therapeutic concepts for clinical application. In April 2018, InflaRx conducted a USD 117 million total gross proceeds follow-on transaction on the US Nasdaq global select market comprised of a primary component of USD 63 million investment into InflaRx as well as a secondary component of USD 54 million to existing first-day shareholders of InflaRx. InflaRx was founded in December 2017 and is headquartered in Jena, Germany.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: Less than $1M
- Total funding: $287.3M
- Funding stage: IPO
- Last round: Post-IPO Equity (Feb 2025)
- Ticker: nasdaq:IFRX
- Website: inflarx.de
- Phone: +49 (0)3641 508 180
Industries & Categories
Health Care, Medical, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/inflarx-130002 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.